Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Stock-Picking Challenge -- Ignore unavailable to you. Want to Upgrade?

To: Oak Tree who wrote (1832)	2/7/2001 11:33:02 PM
From: rupers	Respond to of 2402

Hiya Oak Tree. Yep, guess just the way to look at the news, whether the glass was half full or half empty. Think investors were spooked last fall when they found out FDA had something "negative" to say about the clinical trials (12-month, no booster) last fall. Then, everything went kinda mum, so the recent news, imo, was not really bad. Actually somewhat positive. FDA could have said no statistically significant difference and kaboshed the hopes of having the drug approved. Instead, they seem to agree that the 10 month efficacy was there, but the trials were designed around a 12 month end point, so they tell NABI to go back to the drawing board on defining/designing the trial. Again, not bad, not great news, but NABI's still in the hunt with what appears to be commercially a solid hit if FDA eventually approves it. Meanwhile, NABI is going to conduct on a parallel track some "booster" trials, where the patients get boosters of the drug (don't know why they didn't do that in the first place, but I'm not a biochemist). Still think we'll some accelerated accumulation and wouldn't be surprised to see NABI above 6 by month's end. Just all my opinion, of course. Good luck to ya and ur portfolio.